A new study suggests GLP-1 weight-loss drugs – such as Ozempic – might affect medical imagining scans and interfere with doctors’ ability to detect diseases.

GLP-1 meds, originally developed to treat Type 2 diabetes , have gained widespread popularity due to their weight-loss effects, increasing in usage by 700% in the U.S. between 2019 and 2023, according to the New York Post .

These drugs mimic a natural hormone called GLP-1, which helps regulate blood sugar and appetite, while boosting insulin production, slowing digestion and making people feel full longer.

However, while these biological changes can improve health, they might also interfere with PET-CT scans, which are a tool that doctors use to detect cancer and inflammatory diseases.

PET-CT scans combine two powerful imagi

See Full Page